Abstract：
Psoriasis is an immune-mediated inflammatory disease commonly accompanied by various metabolic disorders. It is widely known that biologics could affect the metabolic status and comorbidities in psoriasis patients, however, the effects of biologics on metabolism in psoriasis patients remain poorly understood. The aim of this study was to elucidate the characteristic changes of metabolic profiling in psoriasis vulgaris (PsV) patients before and after applying biologics. Plasma samples were collected from a retrospective cohort of 43 PsV patients. Non-targeted metabolomics analyses were performed using liquid chromatography-mass spectrometry (LC-MS) to compare the metabolic profiles before and after applying adalimumab (ADA) or ixekizumab (IXE) for 4 weeks. Additionally, correlation analyses were conducted to investigate the associations between metabolite expression levels and clinical characteristics. The biologics significantly affected the metabolic profiles of PsV patients especially in glycerophospholipids (GPs). First, phosphatidylcholine (PC), unsaturated lysophosphatidylcholine (LPC), unsaturated lysophosphatidic acid (LPA) and unsaturated lysophosphatidylethanolamine (LPE) were significantly up-regulated, whereas phosphatidylethanolamine (PE), saturated LPC, saturated LPA and saturated LPE were predominantly down-regulated after biologic treatment. What is more, the changes in PE and LPA were mainly observed after applying IXE instead of ADA. Second, we also found GPs including PC, unsaturated LPC, unsaturated LPA and unsaturated LPE were primarily negatively correlated with disease severity, whereas, PE, saturated LPC, saturated LPA and saturated LPE displayed inverse correlations. Biologics could affect GP metabolism and facilitate the transition of metabolic status from a pro-inflammatory to an anti-inflammatory phenotype in PsV patients.
摘要：
银屑病是一种免疫介导的炎症性疾病，通常伴有各种代谢紊乱。众所周知，生物制剂可影响银屑病患者的代谢状态和合并症，然而,生物制剂对银屑病患者代谢的影响尚不清楚.这项研究的目的是阐明应用生物制剂前后寻常型银屑病（PsV）患者代谢谱的特征性变化。从43名PsV患者的回顾性队列中收集血浆样品。使用液相色谱-质谱（LC-MS）进行非靶向代谢组学分析，以比较应用阿达木单抗（ADA）或ixekizumab（IXE）4周之前和之后的代谢谱。此外,我们进行了相关分析,以研究代谢物表达水平与临床特征之间的关联.生物制剂显着影响PsV患者的代谢谱，尤其是在甘油磷脂（GP）中。首先,磷脂酰胆碱(PC),不饱和溶血磷脂酰胆碱（LPC），不饱和溶血磷脂酸(LPA)和不饱和溶血磷脂酰乙醇胺(LPE)显著上调,而磷脂酰乙醇胺（PE），饱和LPC,生物治疗后饱和LPA和饱和LPE主要下调.更重要的是，应用IXE代替ADA后，主要观察到PE和LPA的变化。第二,我们还发现了包括PC在内的GP,不饱和LPC,不饱和LPA和不饱和LPE主要与疾病严重程度呈负相关，然而,PE,饱和LPC,饱和LPA和饱和LPE呈负相关。生物制剂可以影响GP代谢并促进PsV患者的代谢状态从促炎表型转变为抗炎表型。
